Role of Axumin PET Scan in Germ Cell Tumor

Investigators aim to perform a prospective study of anti-18F-FACBC PET/CT in patients with
NSGCT prior to RPLND, either in the primary setting or in the post-chemotherapy setting. We
will correlate histopathologic outcomes from the RPLND specimen and clinical outcomes of
recurrence during follow-up to identify the accuracy of anti-18F-FACBC PET/CT in these
settings.

Inclusion Criteria:

- Patients with histologically confirmed NSGCT after orchiectomy who are scheduled to
undergo primary RPLND or post-chemotherapy RPLND

- Patients must be over 18 years old and capable and willing to provide informed
consent.

- Medically stable as judged by patient's physician.

- Life expectancy must be estimated at > 6 months.

- Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age
>70 years).

- Patient must be able to lie still for a 20 to 30 minute PET/CT scan. Patients will be
asked if they have problems or issues with lying flat

Exclusion Criteria:

- Patients with known allergic or hypersensitivity reactions to previously administered
radiopharmaceuticals of similar chemical or biologic composition to anti-18F-FACBC are
NOT eligible.

- Patients with liver failure are NOT eligible.

- Patients currently undergoing chemotherapy or chemotherapy within two weeks of
anti-18F-FACBC PET/CT scan are NOT eligible